Back to search results

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Metastatic Castration-resistant Prostate Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of California, Los Angeles, Los Angeles, California, United States

    Contact: Study coordinator (Rosa Lara Vazquez) · ravazquez@mednet.ucla.edu
    Contact: Principal Investigator (Adam E. Singer, MD, PhD)

  • University of California, San Francisco, San Francisco, California, United States

    Contact: Study coordinator (Cody Pham) · cody.pham@ucsf.edu
    Contact: Study coordinator (Danny Avins) · daniel.avins@ucsf.edu
    Contact: Principal Investigator (Kelly Fitzgerald, MD)

  • University of Michigan, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Syntrix Biosystems Clinical Trials) · clinicaltrials@syntrixbio.com
    Contact: Principal Investigator (Zachery R. Reichert, MD, PhD)

  • University of Minnesota, Minneapolis, Minnesota, United States

    Contact: Study coordinator (Syntrix Biosystems Clinical Trials) · clinicaltrials@syntrixbio.com

  • Duke University, Durham, North Carolina, United States

    Contact: Study coordinator (Julia Hurrelbrink) · julia.hurrelbrink@duke.edu
    Contact: Principal Investigator (Andrew J. Armstrong, MD, ScM, FACP)

  • University of Wisconsin, Madison, Wisconsin, United States

    Contact: Study coordinator (UW Carbone Cancer Center - Cancer Connect) · cancerconnect@uwcarbone.wisc.edu · 800-622-8922
    Contact: Principal Investigator (Douglas G. McNeel, MD, PhD)
Study leads

  • Syntrix Biosystems

    Study Director

    Syntrix Biosystems, Inc.

View source on ClinicalTrials.gov(opens in a new tab)